A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the Chinese manufacturer failed to grow its customer base for the first time in five years. But the CDMO remains positive for an uptick this year.
J&J plans $55B US investment over 4 years, including 4 new factories. Construction begins on $2B NC biologics site, creating 500 jobs, following Lilly's $27B US manufacturing pledge.
President Donald Trump on Wednesday announced broad 10% global tariffs in a move that pharma industry groups worry will upend drug costs and manufacturing.
Multiple manufacturing updates: SHL Medical opens $220M SC factory, DHL acquires Cryopdp, AGC forms new division, new facilities for NBE, Siemens-Miko Ghana project, Cellares FDA designation & more industry developments.
Pharma tool and packaging production companies are readying themselves for direct impact from President Donald Trump’s tariffs, which could then have a knock-on effect on their biopharma and CDMO customers.
Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they are “coming in the next month or two.”
Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid Trump's potential pharma tariffs.
Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell out several billion dollars to move manufacturing to the site.
The Trump administration is partnering with Mark Cuban’s compounding business and four other entities to improve the manufacturing of eight generic drugs, in the White House's latest move to boost US drug production.
